You are here: Home:  CCU 3 | 2005: CME Information


Colorectal Cancer Update
A CME Audio Series and Activity

STATEMENT OF NEED/ TARGET AUDIENCE

Colorectal cancer is among the most common cancers in the United States, and the arena of colorectal cancer treatment continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic agents and regimens and changes in indications, doses and schedules for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances.

To bridge the gap between research and patient care, Colorectal Cancer Update utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

  • Critically evaluate the clinical implications of emerging clinical trial data in colorectal cancer treatment and incorporate these data into management strategies in the local and advanced disease settings.
  • Counsel appropriately selected patients about the availability of ongoing clinical trials.
  • Evaluate the emerging data on various adjuvant chemotherapy approaches, including the use of oxaliplatin and capecitabine-containing regimens, and explain the absolute risks and benefits of adjuvant chemotherapy regimens to patients.
  • Integrate emerging data on biologic therapies into management strategies for patients with advanced colorectal cancer.

PURPOSE OF THIS ISSUE OF COLORECTAL CANCER UPDATE

The purpose of Issue 3 of Colorectal Cancer Update is to support these global objectives by offering the perspectives of Drs Saltz, Hoff and O’Connell on the integration of emerging clinical research data into the management of colorectal cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

HOW TO USE THIS MONOGRAPH

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs or tapes, review the monograph and complete the post-test and evaluation form located in the back of this monograph or on our website. This monograph contains edited comments, clinical trial schemas, graphics and references that supplement the audio program. ColorectalCancerUpdate.com includes an easy-to-use interactive version of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue underlined text.

 

Table of Contents Top of Page

Home

Editor’s Note:
Is capecitabine the “AC” of
adjuvant therapy for colorectal cancer?
 
Leonard B Saltz, MD
- Select publications
 
Paulo M Hoff, MD
- Select publications
 
Michael J O’Connell, MD
- Select publications
 

Faculty Disclosures

A CME Audio Series
and Activity

Editor's office

 

Terms of Use and General Disclaimer.
Copyright © 2005 Research To Practice. All Rights Reserved.